News >

Immunotherapy/TKI Combos Continue to Advance RCC Paradigm

Kristi Rosa
Published: Friday, Jul 19, 2019

Claud M. Grigg, Jr, MD

Claud M. Grigg, Jr, MD

With the emergence of immunotherapy/TKI combinations in the treatment paradigm of renal cell carcinoma (RCC), patients are deriving significant benefit with improved survival outcomes, said Claud M. Grigg Jr, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication